CMS Sets Pricing with New HCPCS Codes for eXciteOSA Therapy, Expanding Access to Innovative Daytime Sleep Apnea Treatment

15th November 2023

Signifier Medical Technologies Announces Upcoming Publication of Randomized Controlled Trial Results Examining High-Intensity (Active) Vs. Low-Intensity (Sham) Neuromuscular Electrical Stimulation in Patients for 6 Weeks

1st November 2023

Neuromuscular Electrical Stimulation as a treatment for obstructive sleep apnea gains traction with a recently announced World Sleep 2023 Congress symposium

25th September 2023

Appointment of new Board

25th August 2023

Signifier Medical Technologies Announces Partnership with Sunrise, the company revolutionizing home sleep testing for sleep apnea diagnosis

9th May 2023

Signifier Medical Technologies Wins Edison Award for Innovative Sleep Apnea Treatment

20th April 2023

Nasdaq congratulates Signifier Medical Technologies for treating 10,000 patients with eXciteOSA, a daytime therapy for sleep apnea

29th March 2023

Signifier Medical Technologies Reaches a Wider Patient Population with FDA Approval to Remove Dental Contraindications for eXciteOSA

22nd February 2023

Signifier Medical Technologies Announces Participation In Piper Sandler Healthcare Conference

1st December 2022

Signifier Medical Technologies’ eXciteOSA®, the only FDA-authorized daytime therapy for primary snoring and mild obstructive sleep apnea, demonstrates real-world adherence to treatment of over 80%

21st September 2022